FHTX Q1 2025 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+17.9% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$23M-385.0% margin

Net Income

-$19M-316.4% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+108.4%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$259M

Total Liabilities

$320M

Stockholders' Equity

-$62M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$5M	+17.9%
Gross Profit	$6M	$5M	+17.9%
Operating Income	-$23M	-$28M	+18.7%
Net Income	-$19M	-$25M	+24.7%